Trial Radar IA
Lo studio clinico NCT06735521 (CMR_TCPC) per Cuore univentricolare, Disfunzione microvascolare, Insufficienza cardiaca, Magnetic Resonance è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede

Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation (CMR_TCPC)

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT06735521 (CMR_TCPC) è uno studio osservazionale per Cuore univentricolare, Disfunzione microvascolare, Insufficienza cardiaca, Magnetic Resonance, attualmente in arruolamento. Avviato il 15 aprile 2024, prevede di arruolare 30 partecipanti. Sotto la guida di Karolinska Institutet, dovrebbe concludersi entro il 1 settembre 2025. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 16 dicembre 2024.
Sommario breve
Univentricular heart (UVH) is a severe congenital heart disease. Accurate advanced non-invasive diagnostic methods is limited. Cardiovascular magnetic resonance (CMR) imaging has evolved as a particularly useful tool for the study of patients with adult congenital heart disease (ACHD) considering its ability to determine detailed anatomy and detect early cardiac dysfunction without the need for radiation exposure. Most of contemporary treatment recommendations are based on consensus opinions/documents and small studies from local, or national registries. Improved knowledge is needed in all these areas to facilitate clinical decisions regarding treatment, monitoring and follow-up.

This study seeks to answer if early detection of deterioration in cardiac function, venous pressure and microvascular dysfunction can identify patients before the symptoms progress and thus help to initiate early treatment. The hypothesis is that quantitative myocardial stress-perfusion maps improves the pathophysiological insight in patients with UVH.

The overall goal with this research proposal is to implement combined advanced CMR imaging for a comprehensive non-invasive mapping of functional cardiovascular behavior in patients with complex UVH disease. The outcome of this research may benefit this young adult patient population due to early detection of cardiac disease, less hospitalizations because of heart failure, and eventually decrease morbidity and mortality.

Descrizione dettagliata
CMR is performed supine with a Magnetom Aera® 1.5 Tesla (T) scanner (Siemens Healthcare, Erlangen, Germany), with a phased-array 18-channel body matrix coil and a spine matrix coil. A venous blood sample is drawn to determine hematocrit and blood creatinine prior to imaging. Full coverage retrospective electrocardiographic (ECG)-gated balanced steady state free precession (bSSFP) cine imaging is acquired in standard three long-axis and short-axis slices. Typical imaging parameters are flip angle 68°, pixel size 1.4 × 1.9 mm2, slice thickness 8.0 mm, echo time (TE)/repetition time (TR) 1.19/37.05 ms, matrix size 256 × 144 and field of view (FOV) 360 × 270 mm2.

Using first-pass perfusion imaging, quantitative perfusion maps (ml/min/g) are acquired in one short-axis and one long-axis slice (mid-ventricular, 2-chamber) during administration of an intravenous contrast-agent bolus (0.05 mmol/kg, gadobutrol, Gadovist, Bayer AB, Solna, Sweden), during adenosine infusion (110 µg/kg/min or increased according to clinical routine to 140 µg/kg/min in the absence of adequate response to adenosine (Adenosine, Life Medical AB, Stockholm) and in subsequent rest. Adenosine response is assessed clinically based on symptoms and heart rate response. Adenosine and contrast agent are administered in two different cannulas. Subjects abstained from caffeine for 24 hours prior to CMR examination. A distributed tissue exchange model is used to compute the perfusion maps and the Gadgetron (reconstruction computer) inline perfusion mapping software is used to generate the perfusion maps.Typical imaging parameters were bSSFP single shot readout, flip angel 50°, slice thickness 8.0 mm, TE/TR 1.04/2.5 ms, bandwidth 1085 Hz/pixel, FOV 360 × 270 mm2 and saturation delay/trigger delay (TD) 95/40 ms.

Titolo ufficiale

Att Överleva Och Leva Som Vuxen Med Enkammarhjärta I Sverige

Condizioni
Cuore univentricolareDisfunzione microvascolareInsufficienza cardiacaMagnetic Resonance
Pubblicazioni
Articoli scientifici e documenti di ricerca pubblicati su questo studio clinico:
Altri ID dello studio
  • CMR_TCPC
  • Dnr 2022-04574-01
Numero NCT
Data di inizio (effettiva)
2024-04-15
Ultimo aggiornamento pubblicato
2024-12-16
Data di completamento (stimata)
2025-09-01
Arruolamento (previsto)
30
Tipo di studio
Osservazionale
Stato
In arruolamento
Parole chiave
Fontan circulation
CMR
stress-perfusion
tissue characterization
univentricle heart
TCPC
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Univentricle heart, operated with TCPC (total cavo pulmonary connection)
Cardiac Magnetic Resonance Stress-perfusion
Included patients will be examined at the Karolinska University Hospital in a 1.5T Siemens Sola magnetic resonance camera at rest and during adenosine stress with specific CMR sequences (adenosine stress-perfusion, myocardial velocities, and tissue characterization) for non-invasive determination of macro- and microvascular dysfunction, global myocardial function, pulmonary artery pressure and scarring of the myocardium. Adenosine or Regadenoson will be used as stress medication which is according to clinical routine. Adenosine will be infused over approximately 5 minutes (110-140 μg / kg/min), Regadenoson (5 ml) will be a 10-second injection (400 μg single dosage). Intravenous gadolinium-based contrast agents will be administered, Gadovist (1 mmol/ml, gadobuterol), 0.15 mmol/kg during stress and rest.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Detection of microvascular dysfunction in patients with UVH
This project aims to evaluate microvascular dysfunction using quantitative stress-perfusion CMR in patients with different morphological systemic chamber (left vs right).
Through study completion, an average of 1 year
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
To detect and compare tissue characterization.
Investigate whether positive findings in tissue characterization is higher in different systemic ventricles (left vs right) using T1 and T2-mapping, LGE (late gadolinium enhancement, myocardial scar).
Through study completion, an average of 1 year
Criteri di eleggibilità

Età idonea
Adulto, Adulto anziano
Età minima
18 Years
Sessi idonei
Tutti
  • Patients who had undergone total cavo-pulmonary connection (TCPC) surgery resulting in Fontan circulation.
  • NYHA (New York Heart Assosiation) class I-II.
  • Understanding the study information (signed informed consent).
  • >18 years old.

  • Device therapy (pacemaker, ICD).
  • Failing Fontan (NYHA III-IV).
  • Kidney failure (GFR<30ml/h).
  • Arrythmia (atrial fibrillation).
  • Pregnancy.
Karolinska Institutet logoKarolinska Institutet
Karolinska University Hospital logoKarolinska University Hospital
Parte responsabile dello studio
Peder Sörensson, Investigatore principale, Senior Consultant in Cardiology, Karolinska Institutet
Contatti principali dello studio
Contatto: Peder Sorensson, MD, Associate professor, +46 731 400059, [email protected]
Contatto: Ayse-Gul Ozturk, MD, [email protected]
1 Centri dello studio in 1 paesi
Karolinska University Hospital, Stockholm, 17176, Sweden
Peder Sorensson, MD, Associate professor, Contatto, +46 731 400059, [email protected]
Ayse-Gul Ozturk, MD, Contatto, +46 72 578 02 72, [email protected]
Peder Sorensson, MD, Associate professor, Contatto
In arruolamento